Latest News About - Hepatitis C

 
Show/hide duplicate news articles.
Filter by countryfromabout
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Sunday, March 26, 2017

8:47:00 PM CEST

Subscribe
RSS | MAP

Language Selection

For any category/filter, users can choose:

  1. the language of the categorized news items (e.g. fr and de to display only those news items in French and German)
  2. the language of the user interface (e.g. it for Italian)

In Top Stories, the user can display the largest clusters of news items for one language only (e.g. en shows all clusters in English)

Country Selection

Users can choose:

  1. country mentioned in the news item (articles about a country)
  2. country in which the news item was published (articles from a country)

Languages Collapse menu...Expand menu...Open help...

Select your languages

ar
az
be
bg
bs
ca
cs
da
de
el
en
es
et
fa
fi
fr
ga
ha
he
hi
hr
hu
hy
id
is
it
ja
ka
km
ko
ku
lb
lo
lt
lv
mk
mt
nl
no
pap
pl
ps
pt
ro
ru
rw
se
sk
sl
sq
sr
sv
sw
ta
th
tr
uk
ur
vi
zh
all
Show additional languagesHide additional languages

Interface:

Most reported countries (24h)

Theme countries

AlertLevel (24h)

Alert level graph

 Previous 14 days average

Alert level:
 high   medium   low

Quotes... Extracted quotes

Stuart Schweitzer said: “I see the pharmaceutical industry as extraordinarily vulnerable to failure,” “It’s a very high-risk business. Something like 10 percent of all drugs that are developed get FDA approval. Merck, a couple of years ago, had a drug for inhaled insulin that cost about $2 billion. It was even approved by the FDA, and nobody bought it. It was a failure. They closed it down and sold their patent rights” External link

healthlinenews Thursday, March 23, 2017 7:13:00 PM CET

Stuart Schweitzer said: “I’d like to see legislation that would have the FDA lighten up on the approval regulations,” “So when a drug price has increased by more than, say, 50 percent in a year, the FDA could scare manufacturers away from doing this by ensuring that there’s going to be [a competing product] in the marketplace quite soon. So my answer lies on the supply side, and definitely not price controls, because I don’t believe that we’re going to get as much drug discovery if we take away the motive of making money with a few of our successful drugs” External link

healthlinenews Thursday, March 23, 2017 7:13:00 PM CET

Stuart Schweitzer says: “An example of that is the EpiPen,” “How did they get away with raising their price, and nobody came in and underbid them? You’ve got to look at the FDA’s devices section. The drug in the EpiPen, epinephrine, is a generic drug. There’s no secret to it. The secret is in the delivery system itself. How is it that Mylan developed a really good medical device and nobody else could do that? The FDA devices section takes three years to approve a device, and that really hurt a lot of people. So now there is competition in the market for the EpiPen, but it shouldn’t have taken that long” External link

healthlinenews Thursday, March 23, 2017 7:13:00 PM CET

Teresa Petrangolini spiegato: “Abbiamo aderito con entusiasmo a ENEHIDE perché è strutturato in maniera solida e rigorosa per ottenere risultati in termini di prevenzione e di informazione” External link

247libero Thursday, March 23, 2017 2:48:00 PM CET

Teresa Petrangolini aggiunto: “E’ anche per questo motivo che si spiega l’attenzione della Regione Lazio verso progetti come questo” External link

247libero Thursday, March 23, 2017 2:48:00 PM CET

Craig Robinson explained: "Definitely will be a backwards step in the care of people with significant chronic conditions that we've been able to bring under control- people with hypertension, cardiac problems, diabetes," External link

tristateupdate Thursday, March 23, 2017 12:37:00 PM CET

Peter Szijjarto mondta el: „Már meglévő szolnoki gyárát 5,3 milliárd forintért bővíti. Annak érdekében, hogy még több fém alkatrészt tudjanak előállítani gépjárművek karosszériájához, illetve motorjaihoz. Ehhez a beruházáshoz a kormány 680 millió forintnyi támogatást biztosít, ezáltal száz új munkahely jön létre Szolnokon, illetve Szolnok környékén” External link

hirtv Tuesday, February 21, 2017 8:33:00 AM CET

Most associated names

Daily number of articles in this category

Trend data not available for this selection.